Genetically engineered phages: A review of advances over the last decade

Microbiology and Molecular Biology Reviews

Volumn 80, Issue 3, 2016, Pages 523-543

  Pires, Diana P ^a,b,c   Cleto, Sara ^a,b   Sillankorva, Sanna ^c   Azeredo, Joana ^c   Lu, Timothy K ^a,b  

^a USA   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

^c UNIVERSITY OF MINHO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIBODY; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; OLIGONUCLEOTIDE; VACCINE; VIRUS DNA;

ANTIBACTERIAL ACTIVITY; BACTERIAL GENOME; BACTERIOPHAGE; BACTERIUM DETECTION; CRISPR CAS SYSTEM; DNA SEQUENCE; DRUG DELIVERY SYSTEM; ELECTROPORATION; GENETIC ENGINEERING; GENETIC TRANSCRIPTION; GENOME ANALYSIS; HOMOLOGOUS RECOMBINATION; NONHUMAN; REVIEW; RNA TRANSLATION; BACTERIUM; GENETICS; PHAGE THERAPY; PROCEDURES; VIROLOGY; VIRUS GENOME;

BACTERIA; BACTERIOPHAGES; CRISPR-CAS SYSTEMS; DNA, VIRAL; DRUG DELIVERY SYSTEMS; GENETIC ENGINEERING; GENOME, VIRAL; PHAGE THERAPY;

EID: 84991105090     PISSN: 10922172     EISSN: 10985557     Source Type: Journal    
DOI: 10.1128/MMBR.00069-15     Document Type: Review

References (231)

1. Twort FW. 1915. An investigation on the nature of ultra-microscopic viruses. Lancet 186:1241-1243. http://dx.doi.org/10.1016/S0140-6736 (01) 20383-3.
2. D'Hérelle F. 1917. Sur un microbe invisible antagoniste des bacilles dysentériques. C R Hebd Seances Acad Sci Ser D 165:373-375.
3. Bruynoghe R, Maisin J. 1921. Essais de thérapeutique au moyen du bacteriophage. C R Soc Biol 85:1120-1121.
4. D'Hérelle F. 1921. Le bactériophage: son rôle dans l'immunité. Masson et Cie, Paris, France.
5. Wittebole X, De Roock S, Opal SM. 2014. A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. Virulence 5:226-235. http://dx.doi.org/10.4161/viru.25991.
6. Summers WC. 2004. Bacteriophage research early history, p 528. In Kutter E, Sulakvelidze A (ed), Bacteriophages: biology and applications. CRC Press, Boca Raton, FL.
7. Sulakvelidze A, Alavidze Z, Morris JG. 2001. Bacteriophage therapy. Antimicrob Agents Chemother 45:649-659. http://dx.doi.org/10.1128/AAC.45.3.649-659.2001.
8. Dublanchet A, Fruciano E. 2008. A short history of phage therapy. Med Mal Infect 38:415-420. http://dx.doi.org/10.1016/j.medmal.2008.06.016.
9. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. 2011. Phage treatment of human infections. Bacteriophage 1:66-85. http://dx.doi.org/10.4161/bact.1.2.15845.
10. Chanishvili N. 2012. Phage therapy-history from Twort and d'Herelle through Soviet experience to current approaches. Adv Virus Res 83:3-40. http://dx.doi.org/10.1016/B978-0-12-394438-2.00001-3.
11. Davies J, Davies D. 2010. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev 74:417-433. http://dx.doi.org/10.1128/MMBR.00016-10.
12. Dever LA, Dermody TS. 1991. Mechanisms of bacterial resistance to antibiotics. Arch Intern Med 151:886-895.
13. Neu HC. 1992. The crisis in antibiotic resistance. Science 257:1064-1073. http://dx.doi.org/10.1126/science.257.5073.1064.
14. Wright GD, Sutherland AD. 2007. New strategies for combating multidrugresistant bacteria. Trends Mol Med 13:260-267. http://dx.doi.org/10.1016/j.molmed.2007.04.004.
15. Levy SB, Marshall B. 2004. Antibacterial resistance worldwide: causes, challenges and responses. Nat Med 10:S122-S129. http://dx.doi.org/10.1038/nm1145.
16. CDC. 2013. Antibiotic resistance threats in the United States. CDC, Atlanta, GA.
17. WHO. 2014. Antimicrobial resistance: global report on surveillance. World Health Organization, Geneva, Switzerland.
18. Wright GD. 2007. The antibiotic resistome: the nexus of chemical and genetic diversity. Nat Rev Microbiol 5:175-186. http://dx.doi.org/10.1038/nrmicro1614.
19. Potera C. 2013. Phage renaissance: new hope against antibiotic resistance. Environ Health Perspect 121:a48-a53. http://dx.doi.org/10.1289/ehp. 121-a48.
20. Matsuzaki S, Rashel M, Uchiyama J, Sakurai S, Ujihara T, Kuroda M, Ikeuchi M, Tani T, Fujieda M, Wakiguchi H, Imai S. 2005. Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases. J Infect Chemother 11:211-219. http://dx.doi.org/10.1007/s10156-005-0408-9.
21. Kutateladze M, Adamia R. 2010. Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol 28:591-595. http://dx.doi.org/10.1016/j.tibtech.2010.08.001.
22. Loc-Carrillo C, Abedon ST. 2011. Pros and cons of phage therapy. Bacteriophage 1:111-114. http://dx.doi.org/10.4161/bact.1.2.14590.
23. Weber-Dabrowska B, Mulczyk M, Górski A. 2001. Bacteriophage therapy for infections in cancer patients. Clin Appl Immunol Rev 1:131-134. http://dx.doi.org/10.1016/S1529-1049 (01) 00015-0.
24. Górski A, Miedzybrodzki R, Borysowski J, Weber-Dabrowska B, Lobocka M, Fortuna W, Letkiewicz S, Zimecki M, Filby G. 2009. Bacteriophage therapy for the treatment of infections. Curr Opin Investig Drugs 10:766-774.
25. Kutter E, De Vos D, Gvasalia G, Alavidze Z, Gogokhia L, Kuhl S, Abedon ST. 2010. Phage therapy in clinical practice: treatment of human infections. Curr Pharm Biotechnol 11:69-86. http://dx.doi.org/10.2174/138920110790725401.
26. Yamada T, Kawasaki T, Nagata S, Fujiwara A, Usami S, Fujie M. 2007. New bacteriophages that infect the phytopathogen Ralstonia solanacearum. Microbiology 153:2630-2639. http://dx.doi.org/10.1099/mic.0.2006/001453-0.
27. Jones JB, Jackson LE, Balogh B, Obradovic A, Iriarte FB, Momol MT. 2007. Bacteriophages for plant disease control. Annu Rev Phytopathol 45:245-262. http://dx.doi.org/10.1146/annurev. phyto.45.062806.094411.
28. Adriaenssens EM, Van Vaerenbergh J, Vandenheuvel D, Dunon V, Ceyssens P-J, De Proft M, Kropinski AM, Noben J-P, Maes M, Lavigne R. 2012. T4-related bacteriophage LIMEstone isolates for the control of soft rot on potato caused by "Dickeya solani." PLoS One 7:e33227. http://dx.doi.org/10.1371/journal.pone.0033227.
29. Bae JY, Wu J, Lee HJ, Jo EJ, Murugaiyan S, Chung E, Lee S-W. 2012. Biocontrol potential of a lytic bacteriophage PE204 against bacterial wilt of tomato. J Microbiol Biotechnol 22:1613-1620. http://dx.doi.org/10.4014/jmb.1208.08072.
30. Loessner MJ, Rudolf M, Scherer S. 1997. Evaluation of luciferase reporter bacteriophage A511::luxAB for detection of Listeria monocytogenes in contaminated foods. Appl Environ Microbiol 63:2961-2965.
31. Javed MA, Poshtiban S, Arutyunov D, Evoy S, Szymanski CM. 2013. Bacteriophage receptor binding protein based assays for the simultaneous detection of Campylobacter jejuni and Campylobacter coli. PLoS One 8:e69770. http://dx.doi.org/10.1371/journal.pone.0069770.
32. Fernandes E, Martins VC, Nóbrega C, Carvalho CM, Cardoso FA, Cardoso S, Dias J, Deng D, Kluskens LD, Freitas PP, Azeredo J. 2014. A bacteriophage detection tool for viability assessment of Salmonella cells. Biosens Bioelectron 52:239-246. http://dx.doi.org/10.1016/j.bios.2013.08.053.
33. Schmelcher M, Loessner MJ. 2014. Application of bacteriophages for detection of foodborne pathogens. Bacteriophage 4:e28137. http://dx.doi.org/10.4161/bact.28137.
34. Leverentz B, Conway WS, Camp MJ, Janisiewicz WJ, Abuladze T, Yang M, Saftner R, Sulakvelidze A. 2003. Biocontrol of Listeria monocytogenes on fresh-cut produce by treatment with lytic bacteriophages and a bacteriocin. Appl Environ Microbiol 69:4519-4526. http://dx.doi.org/10.1128/AEM.69.8.4519-4526.2003.
35. Hagens S, Loessner MJ. 2007. Application of bacteriophages for detection and control of foodborne pathogens. Appl Microbiol Biotechnol 76:513-519. http://dx.doi.org/10.1007/s00253-007-1031-8.
36. Bigwood T, Hudson JA, Billington C, Carey-Smith GV, Heinemann JA. 2008. Phage inactivation of foodborne pathogens on cooked and raw meat. Food Microbiol 25:400-406. http://dx.doi.org/10.1016/j.fm.2007.11.003.
37. Spricigo DA, Bardina C, Cortés P, Llagostera M. 2013. Use of a bacteriophage cocktail to control Salmonella in food and the food industry. Int J Food Microbiol 165:169-174. http://dx.doi.org/10.1016/j.ijfoodmicro.2013.05.009.
38. Hyman P, Abedon ST. 2010. Bacteriophage host range and bacterial resistance. Adv Appl Microbiol 70:217-248. http://dx.doi.org/10.1016/S0065-2164 (10) 70007-1.
39. Górski A, Mieądzybrodzki R, Borysowski J, Daąbrowska K, Wierzbicki P, Ohams M, Korczak-Kowalska G, Olszowska-Zaremba N, Łusiak-Szelachowska M, Kłak M, Jończyk E, Kaniuga E, Gołaoe A, Purchla S, Weber-Daąbrowska B, Letkiewicz S, Fortuna W, Szufnarowski K, Pawełczyk Z, Rogózz P, Kłosowska D. 2012. Phage as a modulator of immune responses: practical implications for phage therapy. Adv Virus Res 83:41-71. http://dx.doi.org/10.1016/B978-0-12-394438-2.00002-5.
40. Hagens S, Habel A, Von Ahsen U, Von Gabain A, Bläsi U. 2004. Therapy of experimental Pseudomonas infections with a nonreplicating genetically modified phage. Antimicrob Agents Chemother 48:3817-3822. http://dx.doi.org/10.1128/AAC.48.10.3817-3822.2004.
41. Azeredo J, Sutherland IW. 2008. The use of phages for the removal of infectious biofilms. Curr Pharm Biotechnol 9:261-266. http://dx.doi.org/10.2174/138920108785161604.
42. Labrie SJ, Samson JE, Moineau S. 2010. Bacteriophage resistance mechanisms. Nat Rev Microbiol 8:317-327. http://dx.doi.org/10.1038/nrmicro2315.
43. Samson JE, Magadán AH, Sabri M, Moineau S. 2013. Revenge of the phages: defeating bacterial defences. Nat Rev Microbiol 11:675-687. http://dx.doi.org/10.1038/nrmicro3096.
44. Lu TK, Koeris MS. 2011. The next generation of bacteriophage therapy. Curr Opin Microbiol 14:524-531. http://dx.doi.org/10.1016/j.mib.2011.07.028.
45. Hatfull GF. 2008. Bacteriophage genomics. Curr Opin Microbiol 11:447-453. http://dx.doi.org/10.1016/j.mib.2008.09.004.
46. Klumpp J, Fouts DE, Sozhamannan S. 2012. Next generation sequencing technologies and the changing landscape of phage genomics. Bacteriophage 2:190-199. http://dx.doi.org/10.4161/bact.22111.
47. Barbirz S, Müller JJ, Uetrecht C, Clark AJ, Heinemann U, Seckler R. 2008. Crystal structure of Escherichia coli phage HK620 tailspike: podoviral tailspike endoglycosidase modules are evolutionarily related. Mol Microbiol 69:303-316. http://dx.doi.org/10.1111/j.1365-2958.2008.06311.x.
48. Vegge CS, Brøndsted L, Neve H, McGrath S, Van Sinderen D, Vogensen FK. 2005. Structural characterization and assembly of the distal tail structure of the temperate lactococcal bacteriophage TP901-1. J Bacteriol 187:4187-4197. http://dx.doi.org/10.1128/JB.187.12.4187-4197.2005.
49. Spinelli S, Bebeacua C, Orlov I, Tremblay D, Klaholz BP, Moineau S, Cambillau C. 2014. Cryo-electron microscopy structure of lactococcal siphophage 1358 virion. J Virol 88:8900-8910. http://dx.doi.org/10.1128/JVI.01040-14.
50. Murphy J, Bottacini F, Mahony J, Kelleher P, Neve H, Zomer A, Nauta A, Van Sinderen D. 2016. Comparative genomics and functional analysis of the 936 group of lactococcal Siphoviridae phages. Sci Rep 6:21345. http://dx.doi.org/10.1038/srep21345.
51. Legrand P, Collins B, Blangy S, Murphy J, Spinelli S, Gutierrez C, Richet N, Kellenberger C, Desmyter A, Mahony J, Van Sinderen D, Cambillau C. 2016. The atomic structure of the phage Tuc2009 baseplate tripod suggests that host recognition involves two different carbohydrate binding modules. mBio 7:e01781-15. http://dx.doi.org/10.1128/mBio.01781-15.
52. Tremblay DM, Tegoni M, Spinelli S, Campanacci V, Blangy S, Huyghe C, Desmyter A, Labrie S, Moineau S, Cambillau C. 2006. Receptorbinding protein of Lactococcus lactis phages: identification and characterization of the saccharide receptor-binding site. J Bacteriol 188:2400-2410. http://dx.doi.org/10.1128/JB.188.7.2400-2410.2006.
53. Farenc C, Spinelli S, Vinogradov E, Tremblay D, Blangy S, Sadovskaya I, Moineau S, Cambillau C. 2014. Molecular insights on the recognition of a Lactococcus lactis cell wall pellicle by the phage 1358 receptor binding protein. J Virol 88:7005-7015. http://dx.doi.org/10.1128/JVI.00739-14.
54. Spinelli S, Veesler D, Bebeacua C, Cambillau C. 2014. Structures and host-adhesion mechanisms of lactococcal siphophages. Front Microbiol 5:3. http://dx.doi.org/10.3389/fmicb.2014.00003.
55. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Water P. 2007. Molecular biology of the cell, 5th ed. Garland Science, New York, NY.
56. Snyder L, Peters JE, Henkin TM, Champness W. 2013. Molecular genetics of bacteria, 4th ed. ASM Press, Washington, DC.
57. Friedberg EC. 2003. DNA damage and repair. Nature 421:436-440. http://dx.doi.org/10.1038/nature01408.
58. Lodish H, Berk A, Zipursky SL, Matsudaira P, Baltimore D, Darnell J. 2000. Recombination between homologous DNA sites, section 12.5. In Lodish H, Berk A, Zipursky SL, Matsudaira P, Baltimore D, Darnell J (ed), Molecular cell biology, 4th ed. WH Freeman, New York, NY.
59. Loessner M, Rees C, Stewart G, Scherer S. 1996. Construction of luciferase reporter bacteriophage A511::luxAB for rapid and sensitive detection of viable Listeria cells. Appl Environ Microbiol 62:1133-1140.
60. Le S, He X, Tan Y, Huang G, Zhang L, Lux R, Shi W, Hu F. 2013. Mapping the tail fiber as the receptor binding protein responsible for differential host specificity of Pseudomonas aeruginosa bacteriophages PaP1 and JG004. PLoS One 8:e68562. http://dx.doi.org/10.1371/journal.pone.0068562.
61. Mahichi F, Synnott AJ, Yamamichi K, Osada T, Tanji Y. 2009. Sitespecific recombination of T2 phage using IP008 long tail fiber genes provides a targeted method for expanding host range while retaining lytic activity. FEMS Microbiol Lett 295:211-217. http://dx.doi.org/10.1111/j.1574-6968.2009.01588.x.
62. Sarkis GJ, Jacobs WR, Hatfull GF. 1995. L5 luciferase reporter mycobacteriophages: a sensitive tool for the detection and assay of live mycobacteria. Mol Microbiol 15:1055-1067. http://dx.doi.org/10.1111/j.1365-2958.1995.tb02281.x.
63. Marinelli LJ, Hatfull GF, Piuri M. 2012. Recombineering: a powerful tool for modification of bacteriophage genomes. Bacteriophage 2:5-14. http://dx.doi.org/10.4161/bact.18778.
64. Tanji Y, Furukawa C, Na S-H, Hijikata T, Miyanaga K, Unno H. 2004. Escherichia coli detection by GFP-labeled lysozyme-inactivated T4 bacteriophage. J Biotechnol 114:11-20. http://dx.doi.org/10.1016/j.jbiotec.2004.05.011.
65. Oda M, Morita M, Unno H, Tanji Y. 2004. Rapid detection of Escherichia coli O157:H7 by using green fluorescent protein-labeled PP01 bacteriophage. Appl Environ Microbiol 70:527-534. http://dx.doi.org/10.1128/AEM.70.1.527-534.2004.
66. Marinelli LJ, Piuri M, Swigonová Z, Balachandran A, Oldfield LM, Van Kessel JC, Hatfull GF. 2008. BRED: a simple and powerful tool for constructing mutant and recombinant bacteriophage genomes. PLoS One 3:e3957. http://dx.doi.org/10.1371/journal.pone.0003957.
67. Fehér T, Karcagi I, Blattner FR, Pósfai G. 2012. Bacteriophage recombineering in the lytic state using the lambda red recombinases. Microb Biotechnol 5:466-476. http://dx.doi.org/10.1111/j.1751-7915.2011.00292.x.
68. Shin H, Lee J-H, Yoon H, Kang D-H, Ryu S. 2014. Genomic investigation of lysogen formation and host lysis systems of the Salmonella temperate bacteriophage SPN9CC. Appl Environ Microbiol 80:374-384. http://dx.doi.org/10.1128/AEM.02279-13.
69. Sharan SK, Thomason LC, Kuznetsov SG, Court DL. 2009. Recombineering: a homologous recombination-based method of genetic engineering. Nat Protoc 4:206-223. http://dx.doi.org/10.1038/nprot.2008.227.
70. Oppenheim AB, Rattray AJ, Bubunenko M, Thomason LC, Court DL. 2004. In vivo recombineering of bacteriophage lambda by PCR fragments and single-strand oligonucleotides. Virology 319:185-189. http://dx.doi.org/10.1016/j.virol.2003.11.007.
71. Court DL, Oppenheim AB, Adhya SL. 2007. A new look at bacteriophage lambda genetic networks. J Bacteriol 189:298-304. http://dx.doi.org/10.1128/JB.01215-06.
72. Deveau H, Garneau JE, Moineau S. 2010. CRISPR/Cas system and its role in phage-bacteria interactions. Annu Rev Microbiol 64:475-493. http://dx.doi.org/10.1146/annurev. micro.112408.134123.
73. Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, Romero DA, Horvath P. 2007. CRISPR provides acquired resistance against viruses in prokaryotes. Science 315:1709-1712. http://dx.doi.org/10.1126/science.1138140.
74. Westra ER, Buckling A, Fineran PC. 2014. CRISPR-Cas systems: beyond adaptive immunity. Nat Rev Microbiol 12:317-326. http://dx.doi.org/10.1038/nrmicro3241.
75. Horvath P, Barrangou R. 2010. CRISPR/Cas, the immune system of bacteria and archaea. Science 327:167-170. http://dx.doi.org/10.1126/science.1179555.
76. Garneau JE, Dupuis M-È, Villion M, Romero DA, Barrangou R, Boyaval P, Fremaux C, Horvath P, Magadán AH, Moineau S. 2010. The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature 468:67-71. http://dx.doi.org/10.1038/nature09523.
77. Makarova KS, Haft DH, Barrangou R, Brouns SJJ, Charpentier E, Horvath P, Moineau S, Mojica FJM, Wolf YI, Yakunin AF, Van Der Oost J, Koonin EV. 2011. Evolution and classification of the CRISPRCas systems. Nat Rev Microbiol 9:467-477. http://dx.doi.org/10.1038/nrmicro2577.
78. Makarova KS, Koonin EV. 2013. Evolution and classification of CRISPR-Cas systems and Cas protein families, p 61-91. In Barrangou R, van der Oost J (ed), CRISPR-Cas systems. Springer Berlin Heidelberg, Berlin, Germany.
79. Kiro R, Shitrit D, Qimron U. 2014. Efficient engineering of a bacteriophage genome using the type I-E CRISPR-Cas system. RNA Biol 11:42-44. http://dx.doi.org/10.4161/rna.27766.
80. Martel B, Moineau S. 2014. CRISPR-Cas: an efficient tool for genome engineering of virulent bacteriophages. Nucleic Acids Res 42:9504-9513. http://dx.doi.org/10.1093/nar/gku628.
81. Chan LY, Kosuri S, Endy D. 2005. Refactoring bacteriophage T7. Mol Syst Biol 1:2005.0018.
82. Sanger F, Coulson AR, Friedmann T, Air GM, Barrell BG, Brown NL, Fiddes JC, Hutchison CA, Slocombe PM, Smith M. 1978. The nucleotide sequence of bacteriophage phiX174. J Mol Biol 125:225-246. http://dx.doi.org/10.1016/0022-2836 (78) 90346-7.
83. Smith HO, Hutchison CA, Pfannkoch C, Venter JC. 2003. Generating a synthetic genome by whole genome assembly: phiX174 bacteriophage from synthetic oligonucleotides. Proc Natl Acad Sci U S A 100:15440-15445. http://dx.doi.org/10.1073/pnas.2237126100.
84. Lu TK, Koeris MS, Chevalier B, Holder J, McKenzie G, Brownell D. May 2013. Recombinant phage and methods. US patent 13/627, 060.
85. Ando H, Lemire S, Pires DP, Lu TK. 2015. Engineering modular viral scaffolds for targeted bacterial population editing. Cell Syst 1:187-196. http://dx.doi.org/10.1016/j.cels.2015.08.013.
86. Jaschke PR, Lieberman EK, Rodriguez J, Sierra A, Endy D. 2012. A fully decompressed synthetic bacteriophage φX174 genome assembled and archived in yeast. Virology 434:278-284. http://dx.doi.org/10.1016/j.virol.2012.09.020.
87. Shin J, Jardine P, Noireaux V. 2012. Genome replication, synthesis, and assembly of the bacteriophage T7 in a single cell-free reaction. ACS Synth Biol 1:408-413. http://dx.doi.org/10.1021/sb300049p.
88. Curtin JJ, Donlan RM. 2006. Using bacteriophages to reduce formation of catheter-associated biofilms by Staphylococcus epidermidis. Antimicrob Agents Chemother 50:1268-1275. http://dx.doi.org/10.1128/AAC.50.4.1268-1275.2006.
89. Sillankorva S, Neubauer P, Azeredo J. 2008. Pseudomonas fluorescens biofilms subjected to phage phiIBB-PF7A. BMC Biotechnol 8:79. http://dx.doi.org/10.1186/1472-6750-8-79.
90. Sillankorva S, Neubauer P, Azeredo J. 2010. Phage control of dual species biofilms of Pseudomonas fluorescens and Staphylococcus lentus. Biofouling 26:567-575. http://dx.doi.org/10.1080/08927014.2010.494251.
91. Fu W, Forster T, Mayer O, Curtin JJ, Lehman SM, Donlan RM. 2010. Bacteriophage cocktail for the prevention of biofilm formation by Pseudomonas aeruginosa on catheters in an in vitro model system. Antimicrob Agents Chemother 54:397-404. http://dx.doi.org/10.1128/AAC.00669-09.
92. Rhoads DD, Wolcott RD, Kuskowski MA, Wolcott BM, Ward LS, Sulakvelidze A. 2009. Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J Wound Care 18:237-238, 240-243. http://dx.doi.org/10.12968/jowc.2009.18.6.42801.
93. McVay CS, Velásquez M, Fralick JA. 2007. Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model. Antimicrob Agents Chemother 51:1934-1938. http://dx.doi.org/10.1128/AAC.01028-06.
94. Wright A, Hawkins CH, Anggård EE, Harper DR. 2009. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol 34:349-357. http://dx.doi.org/10.1111/j.1749-4486.2009.01973.x.
95. Carmody LA, Gill JJ, Summer EJ, Sajjan US, Gonzalez CF, Young RF, LiPuma JJ. 2010. Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection. J Infect Dis 201:264-271. http://dx.doi.org/10.1086/649227.
96. Hawkins C, Harper D, Burch D, Anggård E, Soothill J. 2010. Topical treatment of Pseudomonas aeruginosa otitis of dogs with a bacteriophage mixture: a before/after clinical trial. Vet Microbiol 146:309-313. http://dx.doi.org/10.1016/j.vetmic.2010.05.014.
97. Fukuda K, Ishida W, Uchiyama J, Rashel M, Kato S, Morita T, Muraoka A, Sumi T, Matsuzaki S, Daibata M, Fukushima A. 2012. Pseudomonas aeruginosa keratitis in mice: effects of topical bacteriophage KPP12 administration. PLoS One 7:e47742. http://dx.doi.org/10.1371/journal.pone.0047742.
98. Trigo G, Martins TG, Fraga AG, Longatto-Filho A, Castro AG, Azeredo J, Pedrosa J. 2013. Phage therapy is effective against infection by Mycobacterium ulcerans in a murine footpad model. PLoS Negl Trop Dis 7:e2183. http://dx.doi.org/10.1371/journal.pntd.0002183.
99. D'Herelle F. 1931. Bacteriophage as a treatment in acute medical and surgical infections. Bull N Y Acad Med 7:329-348.
100. Rice TB. 1930. Use of bacteriophage filtrates in treatment of suppurative conditions: report of 300 cases. Am J Med Sci 179:345-360. http://dx.doi.org/10.1097/00000441-193003000-00005.
101. Weber-Dabrowska B, Mulczyk M, Górski A. 2000. Bacteriophage therapy of bacterial infections: an update of our institute's experience. Arch Immunol Ther Exp (Warsz) 48:547-551.
102. Mieądzybrodzki R, Borysowski J, Weber-Daąbrowska B, Fortuna W, Letkiewicz S, Szufnarowski K, Pawełczyk Z, Rogózz P, Kłak M, Wojtasik E, Górski A. 2012. Clinical aspects of phage therapy. Adv Virus Res 83:73-121. http://dx.doi.org/10.1016/B978-0-12-394438-2.00003-7.
103. Bruttin A, Brüssow H. 2005. Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob Agents Chemother 49:2874-2878. http://dx.doi.org/10.1128/AAC.49.7.2874-2878.2005.
104. Sarker SA, McCallin S, Barretto C, Berger B, Pittet A-C, Sultana S, Krause L, Huq S, Bibiloni R, Bruttin A, Reuteler G, Brüssow H. 2012. Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh. Virology 434:222-232. http://dx.doi.org/10.1016/j.virol.2012.09.002.
105. Riesenfeld C, Everett M, Piddock LJ, Hall BG. 1997. Adaptive mutations produce resistance to ciprofloxacin. Antimicrob Agents Chemother 41:2059-2060.
106. Alonso A, Campanario E, Martinez JL. 1999. Emergence of multidrugresistant mutants is increased under antibiotic selective pressure in Pseudomonas aeruginosa Microbiology 145:2857-2862. http://dx.doi.org/10.1099/00221287-145-10-2857.
107. Pires D, Sillankorva S, Faustino A, Azeredo J. 2011. Use of newly isolated phages for control of Pseudomonas aeruginosa PAO1 and ATCC 10145 biofilms. Res Microbiol 162:798-806. http://dx.doi.org/10.1016/j.resmic.2011.06.010.
108. Le S, Yao X, Lu S, Tan Y, Rao X, Li M, Jin X, Wang J, Zhao Y, Wu NC, Lux R, He X, Shi W, Hu F. 2014. Chromosomal DNA deletion confers phage resistance to Pseudomonas aeruginosa Sci Rep 4:4738. http://dx.doi.org/10.1038/srep04738.
109. Kim MS, Kim YD, Hong SS, Park K, Ko KS, Myung H. 2015. Phageencoded colanic acid-degrading enzyme permits lytic phage infection of a capsule-forming resistant mutant Escherichia coli strain. Appl Environ Microbiol 81:900-909. http://dx.doi.org/10.1128/AEM.02606-14.
110. Rose T, Verbeken G, Vos DD, Merabishvili M, Vaneechoutte M, Lavigne R, Jennes S, Zizi M, Pirnay J-P. 2014. Experimental phage therapy of burn wound infection: difficult first steps. Int J Burns Trauma 4:66-73.
111. Carvalho CM, Gannon BW, Halfhide DE, Santos SB, Hayes CM, Roe JM, Azeredo J. 2010. The in vivo efficacy of two administration routes of a phage cocktail to reduce numbers of Campylobacter coli and Campylobacter jejuni in chickens. BMC Microbiol 10:232. http://dx.doi.org/10.1186/1471-2180-10-232.
112. Loc Carrillo C, Atterbury RJ, El-Shibiny A, Connerton PL, Dillon E, Scott A, Connerton IF. 2005. Bacteriophage therapy to reduce Campylobacter jejuni colonization of broiler chickens. Appl Environ Microbiol 71:6554-6563. http://dx.doi.org/10.1128/AEM.71.11.6554-6563.2005.
113. Lu TK, Collins JJ. 2009. Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Proc Natl Acad Sci U S A 106:4629-4634. http://dx.doi.org/10.1073/pnas.0800442106.
114. Edgar R, Friedman N, Molshanski-Mor S, Qimron U. 2012. Reversing bacterial resistance to antibiotics by phage-mediated delivery of dominant sensitive genes. Appl Environ Microbiol 78:744-751. http://dx.doi.org/10.1128/AEM.05741-11.
115. Bhattarai SR, Yoo SY, Lee S-W, Dean D. 2012. Engineered phagebased therapeutic materials inhibit Chlamydia trachomatis intracellular infection. Biomaterials 33:5166-5174. http://dx.doi.org/10.1016/j.biomaterials.2012.03.054.
116. Bébéar C, De Barbeyrac B. 2009. Genital Chlamydia trachomatis infections. Clin Microbiol Infect 15:4-10. http://dx.doi.org/10.1111/j.1469-0691.2008.02647.x.
117. Westwater C, Kasman LM, Schofield DA, Werner PA, Dolan JW, Schmidt MG, Norris JS. 2003. Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections. Antimicrob Agents Chemother 47:1301-1307. http://dx.doi.org/10.1128/AAC.47.4.1301-1307.2003.
118. Costerton JW, Stewart PS, Greenberg EP. 1999. Bacterial biofilms: a common cause of persistent infections. Science 284:1318-1322. http://dx.doi.org/10.1126/science.284.5418.1318.
119. O'Toole G, Kaplan HB, Kolter R. 2000. Biofilm formation as microbial development. Annu Rev Microbiol 54:49-79. http://dx.doi.org/10.1146/annurev. micro.54.1.49.
120. Watnick P, Kolter R. 2000. Biofilm, city of microbes. J Bacteriol 182:2675-2679. http://dx.doi.org/10.1128/JB.182.10.2675-2679.2000.
121. Lu TK, Collins JJ. 2007. Dispersing biofilms with engineered enzymatic bacteriophage. Proc Natl Acad Sci U S A 104:11197-11202. http://dx.doi.org/10.1073/pnas.0704624104.
122. Pei R, Lamas-Samanamud GR. 2014. Inhibition of biofilm formation by T7 bacteriophages producing quorum-quenching enzymes. Appl Environ Microbiol 80:5340-5348. http://dx.doi.org/10.1128/AEM.01434-14.
123. Davies DG, Parsek MR, Pearson JP, Iglewski BH, Costerton JW, Greenberg EP. 1998. The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science 280:295-298. http://dx.doi.org/10.1126/science.280.5361.295.
124. Sakuragi Y, Kolter R. 2007. Quorum-sensing regulation of the biofilm matrix genes (pel) of Pseudomonas aeruginosa. J Bacteriol 189:5383-5386. http://dx.doi.org/10.1128/JB.00137-07.
125. Dong YH, Wang LH, Xu JL, Zhang HB, Zhang XF, Zhang LH. 2001. Quenching quorum-sensing-dependent bacterial infection by an N-acyl homoserine lactonase. Nature 411:813-817. http://dx.doi.org/10.1038/35081101.
126. Gu J, Liu X, Li Y, Han W, Lei L, Yang Y, Zhao H, Gao Y, Song J, Lu R, Sun C, Feng X. 2012. A method for generation phage cocktail with great therapeutic potential. PLoS One 7:e31698. http://dx.doi.org/10.1371/journal.pone.0031698.
127. Oliveira A, Sereno R, Azeredo J. 2010. In vivo efficiency evaluation of a phage cocktail in controlling severe colibacillosis in confined conditions and experimental poultry houses. Vet Microbiol 146:303-308. http://dx.doi.org/10.1016/j.vetmic.2010.05.015.
128. Jaiswal A, Koley H, Ghosh A, Palit A, Sarkar B. 2013. Efficacy of cocktail phage therapy in treating Vibrio cholerae infection in rabbit model. Microbes Infect 15:152-156. http://dx.doi.org/10.1016/j.micinf.2012.11.002.
129. Chan BK, Abedon ST, Loc-Carrillo C. 2013. Phage cocktails and the future of phage therapy. Future Microbiol 8:769-783. http://dx.doi.org/10.2217/fmb.13.47.
130. Chan BK, Abedon ST. 2012. Phage therapy pharmacology phage cocktails. Adv Appl Microbiol 78:1-23. http://dx.doi.org/10.1016/B978-0-12-394805-2.00001-4.
131. Yoichi M, Abe M, Miyanaga K, Unno H, Tanji Y. 2005. Alteration of tail fiber protein gp38 enables T2 phage to infect Escherichia coli O157:H7. J Biotechnol 115:101-107. http://dx.doi.org/10.1016/j.jbiotec.2004.08.003.
132. Lin T-Y, Lo Y-H, Tseng P-W, Chang S-F, Lin Y-T, Chen T-S. 2012. A T3 and T7 recombinant phage acquires efficient adsorption and a broader host range. PLoS One 7:e30954. http://dx.doi.org/10.1371/journal.pone.0030954.
133. Marzari R, Sblattero D, Righi M, Bradbury A. 1997. Extending filamentous phage host range by the grafting of a heterologous receptor binding domain. Gene 185:27-33. http://dx.doi.org/10.1016/S0378-1119 (96) 00623-3.
134. Heilpern AJ, Waldor MK. 2003. pIIICTX, a predicted CTXphi minor coat protein, can expand the host range of coliphage fd to include Vibrio cholerae. J Bacteriol 185:1037-1044. http://dx.doi.org/10.1128/JB.185.3.1037-1044.2003.
135. Hodyra-Stefaniak K, Miernikiewicz P, Drapała J, Drab M, Jończyk-Matysiak E, Lecion D, Kaźmierczak Z, Beta W, Majewska J, Harhala M, Bubak B, Kłopot A, Górski A, Daąbrowska K. 2015. Mammalian host-versus-phage immune response determines phage fate in vivo. Sci Rep 5:14802. http://dx.doi.org/10.1038/srep14802.
136. Merril CR, Biswas B, Carlton R, Jensen NC, Creed GJ, Zullo S, Adhya S. 1996. Long-circulating bacteriophage as antibacterial agents. Proc Natl Acad Sci U S A 93:3188-3192. http://dx.doi.org/10.1073/pnas.93.8.3188.
137. Hagens S, Bläsi U. 2003. Genetically modified filamentous phage as bactericidal agents: a pilot study. Lett Appl Microbiol 37:318-323. http://dx.doi.org/10.1046/j.1472-765X.2003.01400.x.
138. Matsuda T, Freeman TA, Hilbert DW, Duff M, Fuortes M, Stapleton PP, Daly JM. 2005. Lysis-deficient bacteriophage therapy decreases endotoxin and inflammatory mediator release and improves survival in a murine peritonitis model. Surgery 137:639-646. http://dx.doi.org/10.1016/j.surg.2005.02.012.
139. Paul VD, Sundarrajan S, Rajagopalan SS, Hariharan S, Kempashanaiah N, Padmanabhan S, Sriram B, Ramachandran J. 2011. Lysisdeficient phages as novel therapeutic agents for controlling bacterial infection. BMC Microbiol 11:195. http://dx.doi.org/10.1186/1471-2180-11-195.
140. Tamma PD, Cosgrove SE, Maragakis LL. 2012. Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev 25:450-470. http://dx.doi.org/10.1128/CMR.05041-11.
141. Citorik RJ, Mimee M, Lu TK. 2014. Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. Nat Biotechnol 32:1141-1145. http://dx.doi.org/10.1038/nbt.3011.
142. Bikard D, Euler CW, Jiang W, Nussenzweig PM, Goldberg GW, Duportet X, Fischetti VA, Marraffini LA. 2014. Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. Nat Biotechnol 32:1146-1150. http://dx.doi.org/10.1038/nbt.3043.
143. Fischetti VA. 2005. Bacteriophage lytic enzymes: novel anti-infectives. Trends Microbiol 13:491-496. http://dx.doi.org/10.1016/j.tim.2005.08.007.
144. Fischetti VA. 2008. Bacteriophage lysins as effective antibacterials. Curr Opin Microbiol 11:393-400. http://dx.doi.org/10.1016/j.mib.2008.09.012.
145. Schmelcher M, Donovan DM, Loessner MJ. 2012. Bacteriophage endolysins as novel antimicrobials. Future Microbiol 7:1147-1171. http://dx.doi.org/10.2217/fmb.12.97.
146. Loessner MJ. 2005. Bacteriophage endolysins-current state of research and applications. Curr Opin Microbiol 8:480-487. http://dx.doi.org/10.1016/j.mib.2005.06.002.
147. Fischetti VA. 2011. Exploiting what phage have evolved to control grampositive pathogens. Bacteriophage 1:188-194. http://dx.doi.org/10.4161/bact.1.4.17747.
148. Fischetti VA. 2010. Bacteriophage endolysins: a novel anti-infective to control Gram-positive pathogens. Int J Med Microbiol 300:357-362. http://dx.doi.org/10.1016/j.ijmm.2010.04.002.
149. Loeffler JM, Nelson D, Fischetti VA. 2001. Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science 294:2170-2172. http://dx.doi.org/10.1126/science.1066869.
150. Nelson D, Loomis L, Fischetti VA. 2001. Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc Natl Acad Sci U S A 98:4107-4112. http://dx.doi.org/10.1073/pnas.061038398.
151. Cheng Q, Nelson D, Zhu S, Fischetti VA. 2005. Removal of group B streptococci colonizing the vagina and oropharynx of mice with a bacteriophage lytic enzyme. Antimicrob Agents Chemother 49:111-117. http://dx.doi.org/10.1128/AAC.49.1.111-117.2005.
152. Loeffler JM, Djurkovic S, Fischetti VA. 2003. Phage lytic enzyme Cpl-1 as a novel antimicrobial for pneumococcal bacteremia. Infect Immun 71:6199-6204. http://dx.doi.org/10.1128/IAI.71.11.6199-6204.2003.
153. Grandgirard D, Loeffler JM, Fischetti VA, Leib SL. 2008. Phage lytic enzyme Cpl-1 for antibacterial therapy in experimental pneumococcal meningitis. J Infect Dis 197:1519-1522. http://dx.doi.org/10.1086/587942.
154. Nelson DC, Schmelcher M, Rodriguez-Rubio L, Klumpp J, Pritchard DG, Dong S, Donovan DM. 2012. Endolysins as antimicrobials. Adv Virus Res 83:299-365. http://dx.doi.org/10.1016/B978-0-12-394438-2.00007-4.
155. Schmelcher M, Powell AM, Camp MJ, Pohl CS, Donovan DM. 2015. Synergistic streptococcal phage λSA2 and B30 endolysins kill streptococci in cow milk and in a mouse model of mastitis. Appl Microbiol Biotechnol 99:8475-8486. http://dx.doi.org/10.1007/s00253-015-6579-0.
156. Díez-Martínez R, De Paz HD, García-Fernández E, Bustamante N, Euler CW, Fischetti VA, Menendez M, García P. 2015. A novel chimeric phage lysin with high in vitro and in vivo bactericidal activity against Streptococcus pneumoniae. J Antimicrob Chemother 70:1763-1773. http://dx.doi.org/10.1093/jac/dkv038.
157. Schmelcher M, Tchang VS, Loessner MJ. 2011. Domain shuffling and module engineering of Listeria phage endolysins for enhanced lytic activity and binding affinity. Microb Biotechnol 4:651-662. http://dx.doi.org/10.1111/j.1751-7915.2011.00263.x.
158. Becker SC, Foster-Frey J, Stodola AJ, Anacker D, Donovan DM. 2009. Differentially conserved staphylococcal SH3b-5 cell wall binding domains confer increased staphylolytic and streptolytic activity to a streptococcal prophage endolysin domain. Gene 443:32-41. http://dx.doi.org/10.1016/j.gene.2009.04.023.
159. Dong Q, Wang J, Yang H, Wei C, Yu J, Zhang Y, Huang Y, Zhang X-E, Wei H. 2015. Construction of a chimeric lysin Ply187N-V12C with extended lytic activity against staphylococci and streptococci. Microb Biotechnol 8:210-220. http://dx.doi.org/10.1111/1751-7915.12166.
160. Yang H, Zhang Y, Yu J, Huang Y, Zhang X-E, Wei H. 2014. Novel chimeric lysin with high-level antimicrobial activity against methicillinresistant Staphylococcus aureus in vitro and in vivo. Antimicrob Agents Chemother 58:536-542. http://dx.doi.org/10.1128/AAC.01793-13.
161. Fernandes S, Proença D, Cantante C, Silva FA, Leandro C, Lourenço S, Milheiriço C, De Lencastre H, Cavaco-Silva P, Pimentel M, São-José C. 2012. Novel chimerical endolysins with broad antimicrobial activity against methicillin-resistant Staphylococcus aureus. Microb Drug Resist 18:333-343. http://dx.doi.org/10.1089/mdr.2012.0025.
162. Walmagh M, Boczkowska B, Grymonprez B, Briers Y, Drulis-Kawa Z, Lavigne R. 2013. Characterization of five novel endolysins from Gramnegative infecting bacteriophages. Appl Microbiol Biotechnol 97:4369-4375. http://dx.doi.org/10.1007/s00253-012-4294-7.
163. Vaara M. 1992. Agents that increase the permeability of the outer membrane. Microbiol Mol Biol Rev 56:395-411.
164. Briers Y, Walmagh M, Lavigne R. 2011. Use of bacteriophage endolysin EL188 and outer membrane permeabilizers against Pseudomonas aeruginosa. J Appl Microbiol 110:778-785. http://dx.doi.org/10.1111/j.1365-2672.2010.04931.x.
165. Yoshida T, Nagasawa T. 2003. ϵ-Poly-L-lysine: microbial production, biodegradation and application potential. Appl Microbiol Biotechnol 62:21-26. http://dx.doi.org/10.1007/s00253-003-1312-9.
166. Amaral KF, Rogero MM, Fock RA, Borelli P, Gavini G. 2007. Cytotoxicity analysis of EDTA and citric acid applied on murine resident macrophages culture. Int Endod J 40:338-343. http://dx.doi.org/10.1111/j.1365-2591.2007.01220.x.
167. Oliveira H, Thiagarajan V, Walmagh M, Sillankorva S, Lavigne R, Neves-Petersen MT, Kluskens LD, Azeredo J. 2014. A thermostable Salmonella phage endolysin, Lys68, with broad bactericidal properties against gram-negative pathogens in presence of weak acids. PLoS One 9:e108376. http://dx.doi.org/10.1371/journal.pone.0108376.
168. Briers Y, Walmagh M, Van Puyenbroeck V, Cornelissen A, Cenens W, Aertsen A, Oliveira H, Azeredo J, Verween G, Pirnay J-P, Miller S, Volckaert G, Lavigne R. 2014. Engineered endolysin-based "Artilysins" to combat multidrug-resistant Gram-negative pathogens. mBio 5:e01379-14. http://dx.doi.org/10.1128/mBio.01379-14.
169. Lood R, Winer BY, Pelzek AJ, Diez-Martinez R, Thandar M, Euler CW, Schuch R, Fischetti VA. 2015. Novel phage lysin capable of killing the multidrug-resistant Gram-negative bacterium Acinetobacter baumannii in a mouse bacteremia model. Antimicrob Agents Chemother 59:1983-1991. http://dx.doi.org/10.1128/AAC.04641-14.
170. Almeida C, Cerqueira L, Azevedo NF, Vieira MJ. 2013. Detection of Salmonella enterica serovar Enteritidis using real time PCR, immunocapture assay, PNA FISH and standard culture methods in different types of food samples. Int J Food Microbiol 161:16-22. http://dx.doi.org/10.1016/j.ijfoodmicro.2012.11.014.
171. Lazcka O, Del Campo FJ, Muñoz FX. 2007. Pathogen detection: a perspective of traditional methods and biosensors. Biosens Bioelectron 22:1205-1217. http://dx.doi.org/10.1016/j.bios.2006.06.036.
172. Almeida C, Sousa JM, Rocha R, Cerqueira L, Fanning S, Azevedo NF, Vieira MJ. 2013. Detection of Escherichia coli O157 by peptide nucleic acid fluorescence in situ hybridization (PNA-FISH) and comparison to a standard culture method. Appl Environ Microbiol 79:6293-6300. http://dx.doi.org/10.1128/AEM.01009-13.
173. Lu TK, Bowers J, Koeris MS. 2013. Advancing bacteriophage-based microbial diagnostics with synthetic biology. Trends Biotechnol 31:325-327. http://dx.doi.org/10.1016/j.tibtech.2013.03.009.
174. Namura M, Hijikata T, Miyanaga K, Tanji Y. 2008. Detection of Escherichia coli with fluorescent labeled phages that have a broad host range to E. coli in sewage water. Biotechnol Prog 24:481-486. http://dx.doi.org/10.1021/bp070326c.
175. Edgar R, McKinstry M, Hwang J, Oppenheim AB, Fekete RA, Giulian G, Merril C, Nagashima K, Adhya S. 2006. High-sensitivity bacterial detection using biotin-tagged phage and quantum-dot nanocomplexes. Proc Natl Acad Sci USA 103:4841-4845. http://dx.doi.org/10.1073/pnas.0601211103.
176. Piuri M, Jacobs WR, Hatfull GF. 2009. Fluoromycobacteriophages for rapid, specific, and sensitive antibiotic susceptibility testing of Mycobacterium tuberculosis. PLoS One 4:e4870. http://dx.doi.org/10.1371/journal.pone.0004870.
177. Rondón L, Piuri M, Jacobs WR, De Waard J, Hatfull GF, Takiff HE. 2011. Evaluation of fluoromycobacteriophages for detecting drug resistance in Mycobacterium tuberculosis. J Clin Microbiol 49:1838-1842. http://dx.doi.org/10.1128/JCM.02476-10.
178. Cappillino M, Shivers RP, Brownell DR, Jacobson B, King J, Kocjan P, Koeris M, Tekeian E, Tempesta A, Bowers J, Crowley E, Bird P, Benzinger J, Fisher K. 2015. Sample6 DETECT/L: an in-plant, in-shift, enrichment-free Listeria environmental assay. J AOAC Int 98:436-444. http://dx.doi.org/10.5740/jaoacint.14-213.
179. Pande J, Szewczyk MM, Grover AK. 2010. Phage display: concept, innovations, applications and future. Biotechnol Adv 28:849-858. http://dx.doi.org/10.1016/j.biotechadv. 2010.07.004.
180. Yacoby I, Shamis M, Bar H, Shabat D, Benhar I. 2006. Targeting antibacterial agents by using drug-carrying filamentous bacteriophages. Antimicrob Agents Chemother 50:2087-2097. http://dx.doi.org/10.1128/AAC.00169-06.
181. Yacoby I, Bar H, Benhar I. 2007. Targeted drug-carrying bacteriophages as antibacterial nanomedicines. Antimicrob Agents Chemother 51:2156-2163. http://dx.doi.org/10.1128/AAC.00163-07.
182. Vaks L, Benhar I. 2011. In vivo characteristics of targeted drug-carrying filamentous bacteriophage nanomedicines. J Nanobiotechnol 9:58. http://dx.doi.org/10.1186/1477-3155-9-58.
183. Bar H, Yacoby I, Benhar I. 2008. Killing cancer cells by targeted drugcarrying phage nanomedicines. BMC Biotechnol 8:37. http://dx.doi.org/10.1186/1472-6750-8-37.
184. Du B, Han H, Wang Z, Kuang L, Wang L, Yu L, Wu M, Zhou Z, Qian M. 2010. Targeted drug delivery to hepatocarcinoma in vivo by phagedisplayed specific binding peptide. Mol Cancer Res 8:135-144. http://dx.doi.org/10.1158/1541-7786. MCR-09-0339.
185. Fagbohun OA, Kazmierczak RA, Petrenko VA, Eisenstark A. 2013. Metastatic prostate cancer cell-specific phage-like particles as a targeted gene-delivery system. J Nanobiotechnol 11:31. http://dx.doi.org/10.1186/1477-3155-11-31.
186. Wang T, Hartner WC, Gillespie JW, Praveen KP, Yang S, Mei LA, Petrenko VA, Torchilin VP. 2014. Enhanced tumor delivery and antitumor activity in vivo of liposomal doxorubicin modified with MCF-7-specific phage fusion protein. Nanomedicine 10:421-430. http://dx.doi.org/10.1016/j.nano. 2013.08.009.
187. Ghosh D, Kohli AG, Moser F, Endy D, Belcher AM. 2012. Refactored M13 bacteriophage as a platform for tumor cell imaging and drug delivery. ACS Synth Biol 1:576-582. http://dx.doi.org/10.1021/sb300052u.
188. Tai IT, Tang MJ. 2008. SPARC in cancer biology: its role in cancer progression and potential for therapy. Drug Resist Updat 11:231-246. http://dx.doi.org/10.1016/j.drup. 2008.08.005.
189. Chen J, Wang M, Xi B, Xue J, He D, Zhang J, Zhao Y. 2012. SPARC is a key regulator of proliferation, apoptosis and invasion in human ovarian cancer. PLoS One 7:e42413. http://dx.doi.org/10.1371/journal.pone.0042413.
190. Miyake H, Hara I, Eto H. 2004. Serum level of cathepsin B and its density in men with prostate cancer as novel markers of disease progression. Anticancer Res 24:2573-2577.
191. Mohamed MM, Sloane BF. 2006. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 6:764-775. http://dx.doi.org/10.1038/nrc1949.
192. Frenkel D, Solomon B. 2002. Filamentous phage as vector-mediated antibody delivery to the brain. Proc Natl Acad Sci U S A 99:5675-5679. http://dx.doi.org/10.1073/pnas.072027199.
193. Butterfield DA, Drake J, Pocernich C, Castegna A. 2001. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid β-peptide. Trends Mol Med 7:548-554. http://dx.doi.org/10.1016/S1471-4914 (01) 02173-6.
194. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T. 2000. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6:916-919. http://dx.doi.org/10.1038/78682.
195. Murphy MP, LeVine H. 2010. Alzheimer's disease and the amyloid-beta peptide. J Alzheimers Dis 19:311-323.
196. Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, Hyman B, Burton MA, Goldstein LE, Duong S, Tanzi RE, Moir RD. 2010. The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS One 5:e9505. http://dx.doi.org/10.1371/journal.pone.0009505.
197. Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, Moore JP, Nabel GJ, Sodroski J, Wilson IA, Wyatt RT. 2004. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 5:233-236. http://dx.doi.org/10.1038/ni0304-233.
198. Sathaliyawala T, Rao M, Maclean DM, Birx DL, Alving CR, Rao VB. 2006. Assembly of human immunodeficiency virus (HIV) antigens on bacteriophage T4: a novel in vitro approach to construct multicomponent HIV vaccines. J Virol 80:7688-7698. http://dx.doi.org/10.1128/JVI.00235-06.
199. Shivachandra SB, Li Q, Peachman KK, Matyas GR, Leppla SH, Alving CR, Rao M, Rao VB. 2007. Multicomponent anthrax toxin display and delivery using bacteriophage T4. Vaccine 25:1225-1235. http://dx.doi.org/10.1016/j.vaccine.2006.10.010.
200. Ren ZJ, Tian CJ, Zhu QS, Zhao MY, Xin AG, Nie WX, Ling SR, Zhu MW, Wu JY, Lan HY, Cao YC, Bi YZ. 2008. Orally delivered foot-andmouth disease virus capsid protomer vaccine displayed on T4 bacteriophage surface: 100% protection from potency challenge in mice. Vaccine 26:1471-1481. http://dx.doi.org/10.1016/j.vaccine.2007.12.053.
201. Lee BY, Zhang J, Zueger C, Chung W-J, Yoo SY, Wang E, Meyer J, Ramesh R, Lee S-W. 2012. Virus-based piezoelectric energy generation. Nat Nanotechnol 7:351-356. http://dx.doi.org/10.1038/nnano. 2012.69.
202. Nam KT, Kim D-W, Yoo PJ, Chiang C-Y, Meethong N, Hammond PT, Chiang Y-M, Belcher AM. 2006. Virus-enabled synthesis and assembly of nanowires for lithium ion battery electrodes. Science 312:885-888. http://dx.doi.org/10.1126/science.1122716.
203. Lee YJ, Yi H, Kim W-J, Kang K, Yun DS, Strano MS, Ceder G, Belcher AM. 2009. Fabricating genetically engineered high-power lithium-ion batteries using multiple virus genes. Science 324:1051-1055. http://dx.doi.org/10.1126/science.1171541.
204. Murugesan M, Abbineni G, Nimmo SL, Cao B, Mao C. 2013. Virusbased photo-responsive nanowires formed by linking site-directed mutagenesis and chemical reaction. Sci Rep 3:1820. http://dx.doi.org/10.1038/srep01820.
205. Mao C, Liu A, Cao B. 2009. Virus-based chemical and biological sensing. Angew Chem Int Ed Engl 48:6790-6810. http://dx.doi.org/10.1002/anie.200900231.
206. Lee J-W, Song J, Hwang MP, Lee KH. 2013. Nanoscale bacteriophage biosensors beyond phage display. Int J Nanomed 8:3917-3925. http://dx.doi.org/10.2147/IJN. S51894.
207. Yi H, Ghosh D, Ham M-H, Qi J, Barone PW, Strano MS, Belcher AM. 2012. M13 phage-functionalized single-walled carbon nanotubes as nanoprobes for second near-infrared window fluorescence imaging of targeted tumors. Nano Lett 12:1176-1183. http://dx.doi.org/10.1021/nl2031663.
208. Rong J, Lee LA, Li K, Harp B, Mello CM, Niu Z, Wang Q. 2008. Oriented cell growth on self-assembled bacteriophage M13 thin films. Chem Commun (Camb) 2008:5185-5187. http://dx.doi.org/10.1039/b811039e.
209. Merzlyak A, Indrakanti S, Lee S-W. 2009. Genetically engineered nanofiberlike viruses for tissue regenerating materials. Nano Lett 9:846-852. http://dx.doi.org/10.1021/nl8036728.
210. Yoo SY, Merzlyak A, Lee S-W. 2014. Synthetic phage for tissue regeneration. Mediators Inflamm 2014:192790. http://dx.doi.org/10.1155/2014/192790.
211. Yang SH, Chung W-J, McFarland S, Lee S-W. 2013. Assembly of bacteriophage into functional materials. Chem Rec 13:43-59. http://dx.doi.org/10.1002/tcr.201200012.
212. Lee S-W, Mao C, Flynn CE, Belcher AM. 2002. Ordering of quantum dots using genetically engineered viruses. Science 296:892-895. http://dx.doi.org/10.1126/science.1068054.
213. Mao C, Flynn CE, Hayhurst A, Sweeney R, Qi J, Georgiou G, Iverson B, Belcher AM. 2003. Viral assembly of oriented quantum dot nanowires. Proc Natl Acad Sci U S A 100:6946-6951. http://dx.doi.org/10.1073/pnas.0832310100.
214. Lee S-W, Wood BM, Belcher AM. 2003. Chiral smectic C structures of virus-based films. Langmuir 19:1592-1598. http://dx.doi.org/10.1021/la026387w.
215. Lee S-W, Lee SK, Belcher AM. 2003. Virus-based alignment of inorganic, organic, and biological nanosized materials. Adv Mater 15:689-692. http://dx.doi.org/10.1002/adma.200304818.
216. Ni J, Lee S-W, White JM, Belcher AM. 2004. Molecular orientation of a ZnS-nanocrystal-modified M13 virus on a silicon substrate. J Polym Sci Part B Polym Phys 42:629-635. http://dx.doi.org/10.1002/polb.10754.
217. Nam KT, Peelle BR, Lee S-W, Belcher AM. 2004. Genetically driven assembly of nanorings based on the M13 virus. Nano Lett 4:23-27. http://dx.doi.org/10.1021/nl0347536.
218. Lee S-W, Belcher AM. 2004. Virus-based fabrication of micro- and nanofibers using electrospinning. Nano Lett 4:387-390. http://dx.doi.org/10.1021/nl034911t.
219. Nam KT, Wartena R, Yoo PJ, Liau FW, Lee YJ, Chiang Y-M, Hammond PT, Belcher AM. 2008. Stamped microbattery electrodes based on self-assembled M13 viruses. Proc Natl Acad Sci U S A 105:17227-17231. http://dx.doi.org/10.1073/pnas.0711620105.
220. Oh D, Qi J, Han B, Zhang G, Carney TJ, Ohmura J, Zhang Y, Shao-Horn Y, Belcher AM. 2014. M13 virus-directed synthesis of nanostructured metal oxides for lithium-oxygen batteries. Nano Lett 14:4837-4845. http://dx.doi.org/10.1021/nl502078m.
221. Dang X, Yi H, Ham M-H, Qi J, Yun DS, Ladewski R, Strano MS, Hammond PT, Belcher AM. 2011. Virus-templated self-assembled singlewalled carbon nanotubes for highly efficient electron collection in photovoltaic devices. Nat Nanotechnol 6:377-384. http://dx.doi.org/10.1038/nnano. 2011.50.
222. Ghosh D, Bagley AF, Na YJ, Birrer MJ, Bhatia SN, Belcher AM. 2014. Deep, noninvasive imaging and surgical guidance of submillimeter tumors using targeted M13-stabilized single-walled carbon nanotubes. Proc Natl Acad Sci U S A 111:13948-13953. http://dx.doi.org/10.1073/pnas.1400821111.
223. Bardhan NM, Ghosh D, Belcher AM. 2014. Carbon nanotubes as in vivo bacterial probes. Nat Commun 5:4918. http://dx.doi.org/10.1038/ncomms5918.
224. Ghosh D, Lee Y, Thomas S, Kohli AG, Yun DS, Belcher AM, Kelly KA. 2012. M13-templated magnetic nanoparticles for targeted in vivo imaging of prostate cancer. Nat Nanotechnol 7:677-682. http://dx.doi.org/10.1038/nnano. 2012.146.
225. Mao JY, Belcher AM, Van Vliet KJ. 2010. Genetically engineered phage fibers and coatings for antibacterial applications. Adv Funct Mater 20:209-214. http://dx.doi.org/10.1002/adfm.200900782.
226. Chung W-J, Merzlyak A, Lee S-W. 2010. Fabrication of engineered M13 bacteriophages into liquid crystalline films and fibers for directional growth and encapsulation of fibroblasts. Soft Matter 6:4454. http://dx.doi.org/10.1039/c0sm00199f.
227. Wang J, Wang L, Yang M, Zhu Y, Tomsia A, Mao C. 2014. Untangling the effects of peptide sequences and nanotopographies in a biomimetic niche for directed differentiation of iPSCs by assemblies of genetically engineered viral nanofibers. Nano Lett 14:6850-6856. http://dx.doi.org/10.1021/nl504358j.
228. Clokie MR, Millard AD, Letarov AV, Heaphy S. 2011. Phages in nature. Bacteriophage 1:31-45. http://dx.doi.org/10.4161/bact.1.1.14942.
229. Hambly E, Suttle CA. 2005. The viriosphere, diversity, and genetic exchange within phage communities. Curr Opin Microbiol 8:444-450. http://dx.doi.org/10.1016/j.mib.2005.06.005.
230. Shendure J, Ji H. 2008. Next-generation DNA sequencing. Nat Biotechnol 26:1135-1145. http://dx.doi.org/10.1038/nbt1486.
231. Mardis ER. 2008. The impact of next-generation sequencing technology on genetics. Trends Genet 24:133-141. http://dx.doi.org/10.1016/j.tig.2007.12.007.